CD101

a novel long-acting echinocandin

Yanan Zhao, Winder B. Perez, Cristina Jiménez-Ortigosa, Grayson Hough, Jeffrey B. Locke, Voon Ong, Ken Bartizal, David S. Perlin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild-type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long-lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.

Original languageEnglish (US)
Pages (from-to)1308-1316
Number of pages9
JournalCellular Microbiology
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Echinocandins
Candida
Invasive Candidiasis
caspofungin
Pharmaceutical Preparations
Mycoses
Candida albicans
Pharmacokinetics
Mutation
Infection
micafungin

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Virology

Cite this

Zhao, Y., Perez, W. B., Jiménez-Ortigosa, C., Hough, G., Locke, J. B., Ong, V., ... Perlin, D. S. (2016). CD101: a novel long-acting echinocandin. Cellular Microbiology, 18(9), 1308-1316. https://doi.org/10.1111/cmi.12640
Zhao, Yanan ; Perez, Winder B. ; Jiménez-Ortigosa, Cristina ; Hough, Grayson ; Locke, Jeffrey B. ; Ong, Voon ; Bartizal, Ken ; Perlin, David S. / CD101 : a novel long-acting echinocandin. In: Cellular Microbiology. 2016 ; Vol. 18, No. 9. pp. 1308-1316.
@article{8bd1b604179740a688dbf0211cf57ea4,
title = "CD101: a novel long-acting echinocandin",
abstract = "CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild-type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long-lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.",
author = "Yanan Zhao and Perez, {Winder B.} and Cristina Jim{\'e}nez-Ortigosa and Grayson Hough and Locke, {Jeffrey B.} and Voon Ong and Ken Bartizal and Perlin, {David S.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/cmi.12640",
language = "English (US)",
volume = "18",
pages = "1308--1316",
journal = "Cellular Microbiology",
issn = "1462-5814",
publisher = "Wiley-Blackwell",
number = "9",

}

Zhao, Y, Perez, WB, Jiménez-Ortigosa, C, Hough, G, Locke, JB, Ong, V, Bartizal, K & Perlin, DS 2016, 'CD101: a novel long-acting echinocandin', Cellular Microbiology, vol. 18, no. 9, pp. 1308-1316. https://doi.org/10.1111/cmi.12640

CD101 : a novel long-acting echinocandin. / Zhao, Yanan; Perez, Winder B.; Jiménez-Ortigosa, Cristina; Hough, Grayson; Locke, Jeffrey B.; Ong, Voon; Bartizal, Ken; Perlin, David S.

In: Cellular Microbiology, Vol. 18, No. 9, 01.09.2016, p. 1308-1316.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CD101

T2 - a novel long-acting echinocandin

AU - Zhao, Yanan

AU - Perez, Winder B.

AU - Jiménez-Ortigosa, Cristina

AU - Hough, Grayson

AU - Locke, Jeffrey B.

AU - Ong, Voon

AU - Bartizal, Ken

AU - Perlin, David S.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild-type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long-lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.

AB - CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates containing fks mutations demonstrated comparable antifungal potency of CD101 relative to micafungin (MCF) across different Candida species. Comparable kinetic inhibition of glucan synthase activity was also observed for CD101 and MCF on both wild-type (WT) and resistant fks mutant Candida strains. Similarly, both drugs yielded nearly identical values for a mutant prevention concentration. In a murine model of invasive candidiasis, CD101 displayed better or at least comparable efficacy relative to MCF in treating WT or fks mutant Candida albicans. An exceptional long-lived pharmacokinetic profile was observed in mice following a single dose of CD101. Collectively, CD101 has great potential not only in treating invasive Candida infections but also in preventing emergence of resistance to currently approved echinocandin drugs.

UR - http://www.scopus.com/inward/record.url?scp=84982135141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982135141&partnerID=8YFLogxK

U2 - 10.1111/cmi.12640

DO - 10.1111/cmi.12640

M3 - Article

VL - 18

SP - 1308

EP - 1316

JO - Cellular Microbiology

JF - Cellular Microbiology

SN - 1462-5814

IS - 9

ER -

Zhao Y, Perez WB, Jiménez-Ortigosa C, Hough G, Locke JB, Ong V et al. CD101: a novel long-acting echinocandin. Cellular Microbiology. 2016 Sep 1;18(9):1308-1316. https://doi.org/10.1111/cmi.12640